Compare Kraft Heinz Co (KHC) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Moderna, Inc. — how do they compare? Kraft Heinz Co trades at $25.76 (market cap $30.66B), while Moderna, Inc. trades at $59.66 (market cap $23.60B). The key difference: Kraft Heinz Co is the larger of the two by market cap, and Kraft Heinz Co pays a 6.19% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| KHC | MRNA | |
|---|---|---|
Market Cap | $30.66B | $23.60B |
Sector | Consumer Staples | Health |
52-Week High | $28.94 | $81.80 |
52-Week Low | $21.21 | $22.36 |
Enterprise Value | $47.71B | $19.70B |
Dividend Yield | 6.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $25.79, down 0.35% on the day. The stock shows a bullish technical trend with moving averages supporting upside, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported a net loss of $5.85 billion in 2025, driving negative profit margins, but has beaten EPS estimates for three consecutive quarters. Recent news highlights a strategic partnership with Disney aimed at brand revitalization.
The outlook remains cautious due to profitability challenges, offset by a high 6.4% dividend yield and undervaluation signals like a P/B of 0.73. Risks include sustained negative earnings and high debt levels. Analyst consensus is mixed, with a hold-heavy rating and a price target below the current price, indicating limited near-term upside potential.
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
